Interventional Medicine R&D

Transcription

1 Interventional Medicine R&D 23 September 2014 Imagine where we can go.

2 Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of BTG plc ( BTG ). These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved. Nothing contained in this presentation or communicated verbally should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. BTG undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances. Neither this presentation nor any verbal communication shall constitute an invitation or inducement to any person to subscribe for or otherwise acquire securities in BTG. 2

3 BTG Interventional Medicine R&D North America Seattle (EKOS) Ottawa (TheraSphere ) Europe Camberley/Farnham (Beads/Varithena ) Frankfurt (Beads) ~200 Employees in Europe and North America engaged in Interventional Medicine R&D activities 3

4 Interventional Medicine Pipeline Activities Disease Product FY13/14 FY20/21 Interventional Medicine: Vascular Varicose veins Varithena Varicose veins Varithena First ex-us approvals Phase 4 Study Venous indication Aesthetic leg vein PEM PEM Phase 3 PRO development Phase 3b Thrombus EkoSonic DVT EkoSonic Pulmonary embolism EkoSonic Product innovation Chronic disease treatment Product innovation Interventional Medicine: Oncology HCC TheraSphere HCC TheraSphere mcrc TheraSphere Embolisation LC Bead /DC Bead Embolisation LC Bead /DC Bead HCC BTG US PMA Phase 3 study (STOP-HCC) Registration study EU/US Phase 3/4 (YES-P) Supportive Label extension for mcrc Phase 3 global 2nd line (EPOCH) Registration study Proprietary new product development Proprietary new product development Proprietary drug bead combination BPH BTG New bead product Post approval clinical Leiomyoma BTG New bead product Post approval clinical Varithena is a registered trademark of Provensis Ltd. EKOS and EkoSonic are trademarks of EKOS Corporation. LC Bead and DC Bead are trademarks of Biocompatibles UK Ltd. Provensis Ltd, EKOS Corporation and Biocompatibles UK Ltd are BTG International group companies. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. 4

5 Interventional Vascular 5

6 Varithena (polidocanol injectable foam) 1% Proprietary combination device to generate pharmaceutical-grade product: Polidocanol Injectable Foam cleared by FDA Delivers microfoam with small and narrow bubble size distribution Benefits in vivo of an ultralow N 2, CO 2 -O 2 based gas formulation Varithena Delivery Device 6

7 Interventional Vascular: Varithena (polidocanol injectable foam) 1% Disease Product FY13/14 FY21+ Varicose veins Varithena Varicose veins Varithena Venous indication Aesthetic leg vein PEM PEM Formulation Concentration Dose Device optimisation 7

8 Interventional Vascular: EKOS Disease Product FY13/14 FY21+ Thrombus EkoSonic Chronic DVT EkoSonic DVT EkoSonic Pulmonary embolism EkoSonic Intelligent Drug Delivery Catheter Ultrasound Core Device Power Size Therapeutic Usability Functionality 8

9 Interventional Oncology 9

10 Interventional Oncology TheraSphere Pipeline US PMA Phase 3 study (STOP-HCC) Registration study EU/US Phase 3/4 study (YES-P) Supportive study TheraSphere Clinical Trial Programme Dosimetry considerations Comparative science Label extension study for mcrc Phase 2 global 2 nd line (EPOCH) Registration study 10

11 Interventional Oncology IO Bead Pipeline Disease Product FY13/14 FY21+ Embolisation LC/DC Bead Embolisation LC/DC Bead Proprietary drug BPH Leiomyoma BTG BTG BTG Post approval clinical Post approval clinical Radiopacity Embolic device (Bioinert) 500 mm Drug eluting device (Bioactivity) Biodegradability 11

12 DC Bead + Contrast Benefits of a Radiopaque DC Bead DSA Fluoroscopy Single shot CBCT (day 7) Radiopaque DC Bead + Contrast Improved intra-procedural guidance and post-procedural feedback 12

13 Interventional Oncology BTG and Philips Collaboration 13

14 Complex tumour CBCT 14

15 In Interventional Medicine we re making giant leaps with smaller, increasingly less invasive steps. Today we can pinpoint the problems inside us and journey within blood vessels to deliver ingenious treatments exactly where they re needed most. And as medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG to help doctors in their quest to see more, reach further and treat smarter. Our growing family of innovators already equip clinicians with tools and techniques that would have seemed like science fiction only a generation ago. We ve set the standards for others to follow, but we re not resting there. Proud as we are of what we do now, we are busy shaping what happens next, because for BTG the race to conquer inner space is always on. With relentless curiosity we ll work with clinicians to find elegant new ways to extend our power over disease. We ll reach the day when intelligent technologies travel through the body as freely as a blood cell, to seek out and eliminate threats to health with molecular accuracy. There are no limits to where our ideas will take us. Imagine where we can go.